Hostname: page-component-89b8bd64d-j4x9h Total loading time: 0 Render date: 2026-05-09T23:24:34.888Z Has data issue: false hasContentIssue false

Assessment of drug-related movement disorders in schizophrenia

Published online by Cambridge University Press:  02 January 2018

Rights & Permissions [Opens in a new window]

Extract

Conventional antipsychotic drugs remain one of the mainstays of treatment of schizophrenia and related psychotic disorders. The therapeutic efficacy of these drugs is well established, both for treatment of acute symptoms and in relapse prevention. Unfortunately, they are associated with a broad range of side-effects, the most prominent of which is the development of a variety of movement disorders (see Box 1). Compared with the conventional antipsychotic agents, the newer, atypical antipsychotics have a lower liability for the acute extrapyramidal side-effects (EPS) and, for a few of the new drugs, there is some evidence of a lower risk of tardive dyskinesia (Barnes & McPhillips, 1999). Nevertheless, even with these newer agents, movement disorders are seen in a significant proportion of patients.

Information

Type
Research Article
Copyright
Copyright © The Royal College of Psychiatrists 2000 
Submit a response

eLetters

No eLetters have been published for this article.